Morocco has taken a significant step in strengthening its position in the vaccine industry with the acquisition of a 10% stake in Resipharm, a global vaccine manufacturer, by the Mohammed VI Investment Fund. This move is part of a broader strategy to enhance the country's capabilities in the production of vaccines and biological products. The acquisition was announced on October 6, 2026, and marks a new phase in the development of the Marbio project, a partnership between the Moroccan government, Resipharm, and the BAB Consortium.
The Marbio project, established in 2021, aims to create a platform for the development and manufacturing of vaccines and biological products in Morocco. The project has already made significant progress, with the establishment of an industrial platform in Benslimane, which is equipped with state-of-the-art facilities for vaccine production. The acquisition of Resipharm's stake by the Mohammed VI Investment Fund is expected to further enhance the project's capabilities and contribute to the growth of Morocco's vaccine industry.
The Mohammed VI Investment Fund, with an initial capital of 15 billion dirhams, plays a crucial role in supporting strategic projects in Morocco. The fund's acquisition of Resipharm's stake in Marbio is part of its broader mandate to invest in key sectors and promote economic growth. Resipharm, a global vaccine manufacturer with operations in several countries, brings significant expertise and experience to the project. The company's withdrawal from the project is part of a structured transition process aimed at ensuring continuity.
The Marbio project has significant implications for Morocco's healthcare sector, as it aims to enhance the country's capabilities in vaccine production and reduce its reliance on imports. The project's focus on developing a platform for the production of vaccines and biological products aligns with Morocco's broader strategy to strengthen its healthcare sector. The acquisition of Resipharm's stake by the Mohammed VI Investment Fund is expected to further boost the project's prospects and contribute to the growth of Morocco's vaccine industry.
The partnership between the Moroccan government, Resipharm, and the BAB Consortium has been instrumental in establishing Marbio as a major player in the vaccine industry. The BAB Consortium, which comprises several major Moroccan banks, has played a significant role in supporting the project. The acquisition of Resipharm's stake by the Mohammed VI Investment Fund marks a new phase in the project's development and is expected to have a positive impact on Morocco's vaccine industry.
Morocco's vaccine industry is expected to benefit significantly from the Marbio project, which aims to develop a platform for the production of vaccines and biological products. The project's focus on enhancing the country's capabilities in vaccine production aligns with Morocco's broader strategy to strengthen its healthcare sector. The acquisition of Resipharm's stake by the Mohammed VI Investment Fund is expected to further boost the project's prospects and contribute to the growth of Morocco's vaccine industry.
The Marbio project is part of Morocco's broader strategy to strengthen its position in the vaccine industry. The project's focus on developing a platform for the production of vaccines and biological products aligns with the country's goal of enhancing its healthcare sector. With the acquisition of Resipharm's stake by the Mohammed VI Investment Fund, the project is expected to make significant progress in the coming years and contribute to the growth of Morocco's vaccine industry.
Key points
- Morocco's sovereign wealth fund acquires 10% stake in vaccine manufacturer Resipharm to boost country's vaccine production capabilities.
